

Special Issue

Basic Studies for Vaccine Development Targeting Virus Infections

Message from the Guest Editors

The first vaccine against a viral infection was developed in 1798 for smallpox by Dr Edward Jenner, who utilized cow pox. This vaccine enabled the eradication of smallpox from the world in 1980. Thus, vaccination is a powerful tool for protection from pathogens, also applicable for the prevention of other diseases, including cancer. Vaccines for many viral infections still need to be developed. Examples of diseases that could be controlled by vaccination are human immunodeficiency virus infection, hepatitis C, respiratory syncytial virus infection, severe acute respiratory syndrome coronavirus-2 disease. This Special Issue focuses on recent progress in the development of vaccines. Also, we welcome application studies of vaccines. This Special Issue aims to contribute to our knowledge of vaccine development and provide an opportunity to spread new information on vaccine research.

Guest Editors

Prof. Dr. Kyoko Tsukiyama-Kohara
Kagoshima University, Kagoshima, Japan

Prof. Dr. Michinori Kohara
Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Deadline for manuscript submissions

closed (30 November 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/62874

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://viruses.mdpi.com)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).